Clinical randomization and trial supplies systems have traditionally focused on managing supplies for sites. The increase in decentralized trials, expedited by the COVID-19 pandemic, has prompted a rapid shift towards more flexible, direct-to-patient models of study supply management and a new emphasis on patient experience. This paper explains how a real-world case study in which Signant helped a sponsor change to a direct-to-patient model mid-study has proven the validity of the model, and it outlines recommendations and best practices when employing a direct-to-patient model of trial supply management.